Keyword: Zika

Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.

Novavax may be years away from a potential approval of its RSV vaccine, but executives aren't waiting to prepare for a possible rollout.

Here's some other vaccine news of note for the week.

Mylan and Biocon win CHMP nod for a Lantus biosimilar, Takeda's Zika vaccine fast-tracked by the FDA, Celltrion got a warning letter.

The WHO stopped classifying Zika as an emergency in late 2016, but Takeda has pressed ahead with its program, winning an FDA fast-track designation.

Here is some other vaccine news of note for the week.

An investment fund formed by J.P. Morgan and the Gates Foundation, Global Health Investment Fund led Themis' €10 million series C.

Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.

Already reeling from bad news on its dengue shot, Sanofi canned its phase 3 C. diff vaccine—and the $500 million-plus in sales that might have come with it.

With financial support from BARDA, Takeda's purified, inactivated, alum-adjuvanted Zika vaccine has entered human testing.